Call for Grant Notification: Genentech Learning and Clinical Integration Team

The Learning and Clinical Integration Team at Genentech, a member of the Roche Group, invites members of the research community to submit applications for innovative research grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific needs exist and funding is available.

Purpose: As part of our scientific mission, Genentech provides grants for scientific projects and fellowship programs that are aligned with our mission to (1) foster advances in scientific research and discovery; and (2) support advanced study by clinical and research professionals at accredited universities or training institutions. Genentech CGNs are posted on the Genentech website (http://funding.gene.com) along with the several social media outlets. In addition, an email is sent out to all registered users of the Genentech Financial Request System (gFRS) who have previously submitted an application for support of an independent education activity.

Eligibility Criteria: Applicant must be registered on the Genentech Financial Request System (gFRS).

Geographical Scope: The research activity must be U.S.-based only unless specifically identified as a Global Grant.

Submission Instructions:

1. Researchers who meet the eligibility criteria and are interested in submitting a response to this CGN submit applications online through gFRS, which can be accessed via http://funding.gene.com. When submitting the application, please be sure the following are completed:
   a. Select the Therapeutic Area, and the Disease State for the grant(s) that you are submitting.
   b. Include “CGN Aug 2016 [Insert Program Title]” as the program title of the grant application
   c. Complete all sections of the online grant request form
   d. Upload all documentation as requested by the system
   e. Deadline for Submission of Application(s): October 24th, 2016 (11:59 PM Pacific Time)

Award Decision Date/Mechanism: Approvals and denials will be communicated via standard grant-submission means (email notifications) no later than November 25th, 2016. There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.

Researchers should not respond to this CGN unless they have read and understand the terms, purpose, therapeutic landscape, and research request identified below. Applicants will be expected to identify independent gaps that are scientifically accurate and relevantly aligned to these CGNs.
### Therapeutic Area and Disease Area

Currently Available CGN(s)

<table>
<thead>
<tr>
<th>Therapeutic Area and Disease Area</th>
<th>[Bleeding Disorders – Hemophilia (1 clinical fellowship up to approximately $200,000)]</th>
</tr>
</thead>
</table>

### Background

Historically, hematology fellowship programs have embraced a dual hematology/oncology focus and certification, yet upon graduation, only 5% of academic physician graduates focus on nonmalignant hematology (1). Federal funding for research on non-malignant blood disorders, has decreased dramatically over the years, showcasing a need to further the field of training in nonmalignant hematology and bleeding disorders (2).

### Methods

Genentech is seeking to help support 1 Hematology fellow initiate her/his career in non-malignant hematology bleeding disorders. The program should be a 1-3 year accredited program within North America.

### Measures and Results

Ideally the supported accredited program will incorporate the expectations outlined by ACGME as well as the following:

1. The highest quality research and clinical training in hematology-bleeding disorders
2. The ability to make impactful contributions to non-malignant hematology bleeding disorder biomedical research and patient care
3. Assuming a key position as a physician-scientist in academia, government or industry, including serving as an important member of preclinical research and development teams

Please note: The fellow cannot have been previously selected prior to the submission or award of the grant, and the program must either have a sole- or majority-focus on non-malignant hematology bleeding disorders.

### Discussion

Researchers who are awarded approval agree to:

1. Demonstrate key findings via outcomes analysis (please see Measures and Results section immediately above)
2. Summarize (through written analysis) the researcher’s understanding of the metrics, identifying the association between the research and the outcomes, identifying any comparison of the results with findings from other identified publications (if relevant)
3. Identify any unanticipated barriers and research limitations explaining the reasons for them, and describing the efforts that were/are being made to adjust them as necessary
4. Be available for discussion and/or presentation if requested by Genentech’s respective Research Manager

*Genentech is also committed to providing non-solicited grant support in all disease areas.*
Additional Considerations

All grant submissions should describe how the proposed research plans to determine the extent to which the initiatives have met the stated objectives and closed the clinical gap(s).

While not required, it is strongly recommended that the results of these research initiatives aim to increase understanding around the elements identified within the chart within this CGN. Genentech will review ways the aforementioned information ties into the following components:

- Research that results in an improvement of quality metrics, quality of care, and/or quality of life
- Research that results in a way to sustainably improve population health for a community
- Additionally, a plan for publishing the results detailing the lessons learned would be welcomed

**Genentech’s Grant Decision-Making Criteria**

Please refer to the publicly available criteria, which can be found at [http://funding.gene.com](http://funding.gene.com).

**Terms and Conditions**

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines.
2. This CGN does not commit Genentech to award a grant or to pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reason, and in fairness to all grantees, all communications about this CGN must come exclusively to Genentech’s department for Learning and Clinical Integration. Failure to comply will automatically disqualify grantees.
5. Failure to follow instruction within this CGN may result in a denial.

**Transparency**

Genentech, at its sole discretion, has the right to disclose the details of funded independent research projects, including those that may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount. The information may be disclosed to the public in a manner including, but not limited to, disclosure on the Genentech website.

**References**